CSE1L Is a Negative Regulator of the RB-DREAM Pathway in p53 Wild-Type NSCLC and Can Be Targeted Using an HDAC1/2 Inhibitor

Scientists identified CSE1L as a novel inhibitor of the RBL2-DREAM pathway and target to activate RBL2-DREAM in NSCLC cells. CSE1L is an oncoprotein that maintains repression of genes that can be reactivated by HDAC inhibitors.